NDAOPHTHALMICSUSPENSION/DROPS
Approved
Jun 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
METIMYD is a fixed-dose ophthalmic suspension combining prednisolone acetate (corticosteroid) and sulfacetamide sodium (sulfonamide antibiotic) for topical treatment of ocular inflammation and bacterial infection. It is used to treat steroid-responsive inflammatory ocular conditions where bacterial infection or risk of infection is present. The corticosteroid reduces inflammation while the antibiotic provides antimicrobial coverage.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30 intensity), the brand team is likely in defensive/optimization mode with potential downsizing rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
METIMYD currently has zero linked job postings, reflecting its declining commercial importance and late-stage lifecycle. Working on this product offers limited advancement potential; career opportunities are shrinking as the brand approaches and enters LOE, with roles focused on defending market share or managing transition to generic status rather than driving growth.
Brand Manager
Worked on METIMYD at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.